



What is claimed is:

1. A compound having the structure



where L is CO or CH₂, X is NH or O, M is a saturated or unsaturated, aliphatic or aromatic, substituted or unsubstituted, straight or branched chain of 0-10 carbon or hetero atoms, Y is an activated functionality selected from the group consisting of active esters, isocyanates, isothiocyanates, thiols, imidoesters, anhydrides, maleimides, thiolactones, diazonium groups, and aldehydes, and R₁ is H, CH₃, C₂H₅, or C₃H₇, R₂ is CH₃ or C₂H₅, and R₃ is a protecting group or H.


2. The compound of claim 1 wherein X is NH, Y is an activated ester, R₁ is CH₃, R₂ is CH₃, and R₃ is a protecting group. [MDMA activated hapten]
3. The compound of claim 1 wherein X is NH, Y is an activated ester, R₁ is C₂H₅, R₂ is CH₃, and R₃ is a protecting group. [MDEA activated hapten]
4. The compound of claim 1 wherein X is NH, Y is an activated ester, R₁ is H, R₂ is CH₃, and R₃ is a protecting group. [MDA activated hapten]
5. A compound having the structure



where L is CO or CH₂, X is NH or O, M is a saturated or unsaturated, aliphatic or aromatic, substituted or unsubstituted, straight or branched chain of 0-10 carbon or hetero atoms, Z is a carrier molecule, R₁ is H, CH₃, C₂H₅, or C₃H₇, and R₂ is CH₃ or C₂H₅.

6. The compound of claim 5 wherein X is NH, Z is selected from the group consisting of KLH, BSA, and aminodextran, R₁ is H, CH₃, or C₂H₅, and R₂ is CH₃ or C₂H₅.
7. Cell line MDMA 8.3, ATCC designation _____, producing a monoclonal antibody having greater than 100% cross-reactivity to MDEA.
8. A monoclonal antibody produced from cell line MDMA 8.3, ATCC designation _____, the antibody having greater than 100% cross-reactivity to MDEA.
9. A monoclonal antibody having greater than 100% cross-reactivity to MDEA and binding in a manner equivalent to that of an antibody from cell line MDMA 8.3, ATCC designation _____.
10. Cell line MDMA 6.1, ATCC designation _____, producing a monoclonal antibody having greater than 90% cross-reactivity to MBDB and *d*-MAMP.
11. A monoclonal antibody produced from cell line MDMA 6.1, ATCC designation _____, the antibody having greater than 90% cross-reactivity to MBDB and *d*-MAMP.
12. A monoclonal antibody having greater than 90% cross-reactivity to MBDB and *d*-MAMP and binding in a manner equivalent to that of an antibody from cell line MDMA 6.1, ATCC designation _____.
13. Cell line MDEA 2.2, ATCC designation _____, producing a monoclonal antibody having greater than 100% cross-reactivity to MDMA and MDBD.
14. A monoclonal antibody produced from cell line MDEA 2.2, ATCC designation _____, the antibody having greater than 100% cross-reactivity to MDMA and MBDB.
15. A monoclonal antibody having greater than 100% cross-reactivity to MDMA and MDBD and binding in a manner equivalent to that of an antibody from cell line MDEA 2.2, ATCC designation _____.

16. An antibody generated in response to a compound having the structure



where L is CO or CH₂, X is NH or O, M is a saturated or unsaturated, aliphatic or aromatic, substituted or unsubstituted, straight or branched chain of 0-10 carbon or hetero atoms, Z is a carrier molecule selected from the group consisting of proteins, polypeptides, and polysaccharides, R₁ is H, CH₃, C₂H₅, or C₃H₇, and R₂ is CH₃ or C₂H₅.

17. The antibody of claim 16 wherein L is CH₂, X is NH, M is OC(CH₂)₂CO, Z is KLH, R₁ is CH₃ or C₂H₅, and R₂ is CH₃. [This covers immunogens **1P** (R₁=CH₃) and **2U** (R₁=C₂H₅), which gave rise to the claimed mabs.]